The American biotech firm Alzheon has unveiled data being presented at the Alzheimer’s Association International Conference (AAIC), in London.
The company is conducting a Phase III program investigating ALZ-801, an anti-amyloid drug candidate, as a potential treatment for Alzheimer’s disease.
ALZ-801 is an optimized prodrug of tramiprosate. A prodrug is a compound that is metabolized into a pharmacologically active drug after it has been administered.